Savant Capital LLC Decreases Stock Holdings in Stryker Corporation $SYK

Savant Capital LLC trimmed its holdings in shares of Stryker Corporation (NYSE:SYK) by 30.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 6,260 shares of the medical technology company’s stock after selling 2,784 shares during the period. Savant Capital LLC’s holdings in Stryker were worth $2,200,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of SYK. Brighton Jones LLC increased its position in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new stake in shares of Stryker during the second quarter valued at approximately $205,000. Marshall Wace LLP increased its position in shares of Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after acquiring an additional 77,831 shares during the last quarter. Nebula Research & Development LLC purchased a new stake in shares of Stryker during the second quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC purchased a new stake in shares of Stryker during the second quarter valued at approximately $253,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,264 shares of company stock valued at $100,659,489 over the last three months. Company insiders own 4.60% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $305.73 on Monday. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The business has a fifty day moving average price of $321.82 and a 200-day moving average price of $348.10. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The firm has a market capitalization of $117.21 billion, a P/E ratio of 35.39, a PEG ratio of 1.92 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the previous year, the business earned $2.84 earnings per share. Stryker’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SYK. Evercore set a $355.00 price target on Stryker in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research report on Friday, May 1st. Needham & Company LLC decreased their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Barclays decreased their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Finally, UBS Group decreased their target price on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.